Why Is Pain Treatment Focused Heron Therapeutics Stock Trading Higher Today?

Zinger Key Points
  • The company revised Q4FY23 projections, outlined FY24 outlook, emphasizing product potential and operational enhancements
  • Heron Therapeutics implemented a cost reduction plan to decrease operating expenses by 26% in 2023

Heron Therapeutics Inc HRTX reported Q3 sales of $31.43 million, missing the consensus of $32.75 million.

The company reported a Q3 EPS loss of $(0.17), lower than $(0.38) a year, and beating the consensus of $(0.29).

The company implemented a cost reduction plan to decrease operating expenses by 26% in 2023 compared to 2022, and full-year 2024 operating expenses to be around $108 million-$116 million.

The company sees FY23 sales of $123 million-$125 million compared to a prior range of $99 million-$103 million and a consensus of $124.61 million.

The company forecasts FY24 sales of $138 million-$158 million versus a consensus of $156.57 million.

Needham noted that the guidance parameters highlight the company's restructuring and cost reduction progress and map a path to operating cash flow breakeven by YE2024. 

EBITDA targets hinges on the stability of the Chemotherapy Induced Nausea and Vomiting franchise and the growth of Zynrelef, which should see a label expansion in early 2024 and a vial access needle modification in September 2024.

Needham maintains the Buy rating with a price target of $4 and expects it will take a few quarters of execution and improving sales to demonstrate progress towards the proposed profitability path.

Price Action: HRTX shares are up 61.40% at $0.87 on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Analyst ColorBiotechEarningsNewsPenny StocksGuidanceHealth CareAnalyst RatingsMoversTrading IdeasGeneralBriefsExpert Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!